Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00447
|
|||||
| Drug Name |
Nevirapine
|
|||||
| Synonyms |
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; BI RG 587; BI-RG-587; BI-RG-587 & CD4-IgG; BIRG 0587; BIRG 587; BIRG-0587; BIRG-587; BIRG587; Cahill May Roberts Brand of Nevirapine; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; NEV; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; NVP; Nevirapine & CD4-IgG; Nevirapine & PRO 140; Nevirapine (JAN/USP/INN); Nevirapine [USAN:INN]; Promeco Brand of Nevirapine; Viramune; Viramune (TN); Viramune(TM); Viramune, BI-RG 587, Nevirapine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Human immunodeficiency virus infection [ICD11: 1C62.Z] | Approved | [1] | |||
| Therapeutic Class |
Anti-HIV Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H14N4O
|
|||||
| Canonical SMILES |
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
|
|||||
| InChI |
InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
|
|||||
| InChIKey |
NQDJXKOVJZTUJA-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 129618-40-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 266.3 | Topological Polar Surface Area | 58.1 | ||
| Heavy Atom Count | 20 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
12014582
, 14716699
, 14716702
, 14872507
, 17388862
, 24721613
, 26718578
, 26719643
, 29223558
, 46386569
, 46393424
, 46394249
, 46506789
, 48425381
, 49718173
, 49856363
, 500792
, 50086444
, 50622552
, 53789571
, 5596797
, 56313692
, 56313770
, 57322283
, 597607
, 601303
, 7847501
, 7889356
, 7889505
, 7980115
, 8031304
, 81093307
, 8152750
, 819817
, 823573
, 823576
, 826050
, 826057
, 826059
, 826060
, 832211
, 832214
, 833983
, 85173516
, 865943
, 866527
, 92308419
, 92712790
, 93166484
, 9472
|
|||||
| ChEBI ID |
ChEBI:63613
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Nevirapine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.